FeesSafety
Pluang+

Pralsetinib shows 53% response rate in RET fusion-positive tumors, with strong results in lung and thyroid cancers.

Market News
19 Oct 2026, 15:05 WIB
PRNewsWire
View Source
Bullish
Pralsetinib shows 53% response rate in RET fusion-positive tumors, with strong results in lung and thyroid cancers.

Rigel Pharmaceuticals announced that pooled data from two trials, ARROW and TAPISTRY, show pralsetinib achieves a 53% overall response rate in patients with RET fusion-positive solid tumors, including lung and thyroid cancers. The drug demonstrated durable effectiveness, especially in first-line treatment for RET fusion-positive non-small cell lung cancer (NSCLC), with improved patient quality of life. These findings support pralsetinib's potential as a tumor-agnostic therapy and reinforce its role as a first-line treatment option for RET fusion-positive cancers. Further clinical data will be presented at the ESMO Congress 2026.

The news on Rigel Pharmaceuticals' pralsetinib data is presented with Pluang's Health sector market context. Of 150 priced Health-sector US stocks on Pluang, 68 rose and 54 fell today. Notable movers include Heron Therapeutics Inc (HRTX) at USD 0.37 with a 2.49% increase, Revolution Medicines Inc. (RVMD) at USD 181.96 up 2.25%, and Arrowhead Pharmaceuticals Inc. (ARWR) at USD 56.94 rising 1.86%, as of Oct 19, 2026 18:43 WIB.

More News

Gorilla Technology posts record $69.5M Q3 revenue, targets $200M in 2026 amid AI infrastructure growth

Gorilla Technology posts record $69.5M Q3 revenue, targets $200M in 2026 amid AI infrastructure growth

Gorilla Technology reported a record $69.5 million in revenue for Q3 2026, driven by expanding AI infrastructure projects and hardware deliveries. The company reduced unbilled contract assets by over 50%, improving liquidity as it shifts focus from s...

Company Fundamentals
Bullish
30 minutes ago
Berkshire Hathaway holds steady on Apple shares despite 29% price rise and high valuation in 2026.

Berkshire Hathaway holds steady on Apple shares despite 29% price rise and high valuation in 2026.

Berkshire Hathaway has not sold any Apple shares in 2026, even as Apple's stock price rose 29% and its price-to-earnings ratio neared 40, indicating less concern about valuation. This decision reflects confidence in Apple's strong business fundamenta...

Market News
Bullish
34 minutes ago
US invests $1.6B to build domestic rare-earth supply chain with USA Rare Earth leading Texas mine development.

US invests $1.6B to build domestic rare-earth supply chain with USA Rare Earth leading Texas mine development.

The U.S. government is investing $1.6 billion to develop a domestic rare-earth supply chain, aiming to reduce reliance on China. USA Rare Earth is a key player, using the funds to build out mining and processing capabilities, including developing the...

Market News
Bullish
39 minutes ago
Alamar Biosciences raises 2026 revenue forecast to $121-$123M, driven by biopharma demand and clinical diagnostics expansion.

Alamar Biosciences raises 2026 revenue forecast to $121-$123M, driven by biopharma demand and clinical diagnostics expansion.

Alamar Biosciences increased its full-year 2026 revenue guidance to $121-$123 million, fueled by strong demand for consumables from biopharmaceutical clients who now represent 49% of Q3 revenue. The company’s NULISA platform was selected by the U.K. ...

Company Fundamentals
Bullish
39 minutes ago
CeriBell raises 2026 revenue forecast to $115-$117M, boosts hospital accounts and gross margin to 90%.

CeriBell raises 2026 revenue forecast to $115-$117M, boosts hospital accounts and gross margin to 90%.

CeriBell updated its full-year 2026 revenue guidance to $115 million to $117 million, driven by increased usage per hospital account and expansion by 35 new hospital accounts. The company improved its gross margin to 90% from 88% last year, supported...

Company Fundamentals
Bullish
39 minutes ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App